In The News,
ADVI’s Lindsay Bealor Greenleaf caught up with BioWorld to discuss drug prices and how recent proposals would impact patient access to new cures and treatments.
[el-text]
***excerpt***
“A government price-setting model that links to foreign countries’ payment designs puts the speedy access to innovative therapies that we enjoy today at serious risk,” Lindsay Bealor Greenleaf, director of policy at ADVI Health, told BioWorld. “That is a dangerous combination for patient access to current treatments and the development of new cures,” she continued. “Compared to the rest of the world, the U.S. places a high value on access to therapies, which is why Americans currently enjoy access to cancer treatments about two years earlier than other developed countries.”
***end excerpt***
[/el-text]